IMPACT BIOMEDICAL INC.
Close on Oct 19, 2026
- Market cap
- $329.93M
- P/E (TTM)
- –
- Dividend yield
- –
About Impact Biomedical
Pharmaceutical Preparations, SIC 2834
Impact BioMedical Inc. is a biotechnology company focused on the discovery, development, and patenting of science and technologies for human healthcare and wellness. The company operates in a single biotechnology business segment, targeting the prevention, inhibition, and treatment of neurological, oncological, and inflammatory conditions, as well as infectious diseases. Key product candidates and platforms include Linebacker for oncology and inflammatory disorders, Laetose as a low-glycemic alternative sugar formulation, Equivir for antiviral applications, and the 3F suite of functional fragrances. Its commercialization strategy centers on licensing and partnering with pharmaceutical, food, and consumer packaged goods companies.
The company operates primarily through subsidiaries such as Global BioLife, Impact BioLife Science, Global BioMedical, and Sweet Sense. Its corporate headquarters are located in Houston, Texas. Impact BioMedical maintains intellectual property portfolio rights consisting of sixty-nine issued patents and more than sixty pending patent applications worldwide.
Summary of the business section of Impact Biomedical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IMPACT BIOMEDICAL INC.
- Founded
- 2018
- Headquarters
- West Henrietta, NY
- Address
- 275 Wiregrass Pkwy, 14586
- Phone
- (585) 232-1500
- Website
- impactbiomedinc.com
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- GRASSI & CO., CPAs, P.C., Jericho, New York
Stock & identifiers
- Ticker
- IBO
- Exchange
- NYSE
- Shares outstanding
- 108M, Aug 4, 2026
- Public float
- $7.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1834105
- CUSIP
- 04529L106
- ISIN
- US04529L1062
- EIN
- 85-3926944
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Frank D. Heuszel | Chief Executive Officer, Director | 97,344 |
| Todd D. Macko | Chief Financial Officer | 155,122 |
| Jason Grady | Director | 250,182 |
| Heng Fai Ambrose Chan | Director | 0 |
Employees
Headcount reported in annual reports
“Company currently has two full-time employee and six shared employees with DSS as of December 31, 2025.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 8, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |